La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Alzamend Neuro a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Alzamend Neuro..

Alzamend Neuro (NASDAQ:ALZN) Azioni, Catena delle Opzioni

Alzamend Neuro

Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Its mission is to develop and market safe and effective treatments. The company's pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's.

Alzamend Neuro Inc

Shares of Elastic N.V (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ESTC#NYSE">ESTC</a>) rose sharply in today's pre-market trading after the company reported better-than-expected second-quarter financial results and issued FY25 guidance <a href="https://www.benzinga.com/quote/ESTC/news">above estimates</a>.
Elastic reported quarterly earnings of 59 cents per share which beat the analyst consensus estimate of 38 cents per share. The company reported quarterly sales of $365.361 million which beat the analyst consensus estimate of $355.900 million.
Elastic shares jumped 29.1% to $121.46 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Virpax Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRPX#NASDAQ">VRPX</a>) gained 67.1% to $0.9855 in pre-market trading after the company announced an agreement with the US HHS department for an extension towards its cooperative research and development.</li>
<li>Wellchange Holdings Company Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WCT#NASDAQ">WCT</a>) rose 50.4% to $1.88 in pre-market trading after dipping 62% on Thursday.</li>
<li>Beneficient  (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BENF#NASDAQ">BENF</a>) gained 30.7% to $1.15 in pre-market trading after gaining around 7% on Thursday.</li>
<li>SKK Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SKK#NASDAQ">SKK</a>) gained 25.4% to $1.38 in pre-market trading after declining around 75% on Wednesday.</li>
<li>Exicure, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XCUR#NASDAQ">XCUR</a>) gained 19.4% to $12.98 in pre-market trading.</li>
<li>The Gap, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GAP#NYSE">GAP</a>) gained 14.9% to $25.33 in pre-market trading after reporting better-than-expected third-quarter results.</li>
<li>Global Blue Group Holding AG (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GB#NYSE">GB</a>) gained 10.4% to $6.90 in pre-market trading.</li>
<li>Kairos Pharma, Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KAPA#NYSE">KAPA</a>) climbed 8.7% to $1.63 in pre-market trading.</li>
<li>Ross Stores, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROST#NASDAQ">ROST</a>) gained 7% to $153.01 in pre-market trading after the company reported better-than-expected third-quarter EPS results..</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Knightscope, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KSCP#NASDAQ">KSCP</a>) shares tumbled 41.8% to $10.64 in pre-market trading after the company announced the pricing of $12.1 million public offering.</li>
<li>Autonomix Medical, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMIX#NASDAQ">AMIX</a>) fell 33.3% to $9.01 in pre-market trading.</li>
<li>Cemtrex, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CETX#NASDAQ">CETX</a>) shares fell 27.2% to $0.1430 in pre-market trading after the company announced its board approved a 1-for-35 reverse stock split.</li>
<li>Procaps Group S.A. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PROC#NASDAQ">PROC</a>) declined 18.7% to $0.90 in pre-market trading as the company said it faced Nasdaq delisting threat due to Form 20-F filing delay.</li>
<li>Carter Bankshares, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CARE#NASDAQ">CARE</a>) shares fell 10.6% to $16.86 in pre-market trading.</li>
<li>Real Messenger Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RMSG#NASDAQ">RMSG</a>) dipped 16.2% to $3.51 in pre-market trading after jumping over 10% on Thursday.</li>
<li>Aptose Biosciences Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APTO#NASDAQ">APTO</a>) fell 13.9% to $0.21 in pre-market trading after dipping more than 10% on Thursday.</li>
<li>Envoy Medical, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COCH#NASDAQ">COCH</a>) shares dipped 12.7% to $1.92 in pre-market trading.</li>
<li>Reddit, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDDT#NYSE">RDDT</a>) fell 7.3% to $146.50 in pre-market trading. Reddit's shareholder, Advance Magazine Publishers Inc. plans to sell as much as $1.2 billion of the company's stake, reported Bloomberg on Friday morning. The company is said to be offering 7.8 million shares in between the range of $145.38-$148.54 each.</li>
<li>Intuit Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTU#NASDAQ">INTU</a>) fell 5.7% to $639.95 in today's pre-market trading. Intuit reported upbeat results for its first-quarter results, but issued weak forecast for the current quarter.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/24/11/42131399/dow-surges-over-450-points-investor-sentiment-improves-fear-greed-index-moves-to-greed-zone">Dow Surges Over 450 Points As Nvidia Climbs Post-Earnings, Google, Amazon Slip: Fear Index Shifts To &#8216;Greed&#8217; Zone</a></li>
</ul>

AMIX

APTO

BENF

CARE

CETX

Envoy Medical, Inc. - Class A Common Stock

COCH

ESTC

INTU

KAPA

KSCP

PROC

RDDT

RMSG

ROST

VRPX

XCUR

Why Elastic Shares Are Trading Higher By 29%; Here Are 20 Stocks Moving Premarket

Needham analyst Tom Nikic initiates coverage on Foot Locker (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FL#NYSE">FL</a>) with a Buy rating and announces Price Target of $27.

News

Price Target

Initiation

Analyst Ratings

Needham Initiates Coverage On Foot Locker with Buy Rating, Announces Price Target of $27

Needham analyst Mike Matson downgrades TransMedics Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMDX#NASDAQ">TMDX</a>) from Buy to Hold and maintains the price target from $109 to $109.

Downgrades

TMDX

Needham Downgrades TransMedics Gr to Hold, Maintains Price Target to $109

Needham analyst Tom Nikic initiates coverage on Nike (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NKE#NYSE">NKE</a>) with a Buy rating and announces Price Target of $84.

Needham Initiates Coverage On Nike with Buy Rating, Announces Price Target of $84

ZKH Group Inks Pact With With Zhejiang Tmall Technology Co. To Establish Cooperation Of GBB Platform With Zhejiang Tmall's Industrial Product Platform; Agreement Will Be Effective Until October 31

Needham analyst Tom Nikic reiterates Under Armour (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UAA#NYSE">UAA</a>) with a Hold.

Reiteration

Needham Reiterates Hold on Under Armour

Needham analyst Tom Nikic initiates coverage on On Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ONON#NYSE">ONON</a>) with a Buy rating and announces Price Target of $64.

ONON

Needham Initiates Coverage On On Holding with Buy Rating, Announces Price Target of $64

The Starship&#8216;s many engines are isolated from each other, preventing the risk of one engine failure causing failure of all as in the case of the Soviet Union&#8217;s N1 rocket, SpaceX CEO Elon Musk said on Thursday.
What Happened: &#8220;If engine failures are isolated from each other and the primary airframe, then more engines &#x2A;increases&#x2A; reliability,&#8221; Musk said in a post on social media platform X. &#8220;The problem with N-1 was that a failure of any engine caused failure of all.&#8221;
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">If engine failures are isolated from each other and the primary airframe, then more engines &#x2A;increases&#x2A; reliability. The problem with N-1 was that a failure of any engine caused failure of all.
&mdash; Elon Musk (@elonmusk) <a href="https://twitter.com/elonmusk/status/1859667589817041394?ref_src=twsrc%5Etfw">November 21, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
The Starship has often been compared to the Soviet N1 rocket owing to its large number of engines. Musk himself has admitted that the <a href="https://www.benzinga.com/news/23/05/32566212/elon-musk-reacts-to-comparison-of-starship-with-doomed-rocket-that-knocked-soviet-union-out-of-moon">N1 is the closest comparable rocket to Starship</a>. However, the Starship has 33 engines on its Super Heavy booster, even more than the 30 engines on the Soviet N1&#8217;s first stage.
About N1: N1 was aimed at enabling crewed travel to the moon. However, all four attempts to launch failed and the program was suspended in 1974.
The Soviets carried out a clandestine launch of the N1 on July 3, 1969, which ended up in a colossal explosion. This effectively knocked out the Soviet Union from the Moon race just days before U.S. astronauts walked on the surface of the moon.
About Starship: Starship is SpaceX&#8217;s most ambitious launch vehicle aimed at taking humans back to the Moon and Earth&#8217;s neighboring planet Mars. 
The company has conducted six test flights of the vehicle thus far but without a payload. The last flight test took place earlier this week and NASA is looking forward to taking humans back to the surface of the Moon after a gap of over 50 years with the help of a <a href="https://www.benzinga.com/24/11/42108681/spacex-shows-off-conceptual-version-of-starship-which-will-help-humans-land-back-on-moon-in-over-50-yrs">custom version of Starship</a>.
Check out more of Benzinga's Future Of Mobility coverage by&nbsp;<a href="https://www.benzinga.com/topic/mobility" target="_blank" rel="noreferrer noopener">following this link.</a>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/11/42131163/tesla-ceo-elon-musk-attempts-to-temper-down-expectations-of-30k-optimus-or-cybercab-soon">Tesla CEO Elon Musk Tries To Lower Expectations Of $30K Optimus Or Cybercab</a></li>
</ul>
Photo courtesy: SpaceX

SPACE

Markets

Tech

General

SpaceX CEO Elon Musk Explains How Starship's Engine Design Prevents Chain Failures Unlike Soviet N1 Rocket

ZKH Group Q3 Adj EPS $(0.06), Sales $324.995M; Exits Quarter With Cash & Equivalents Worth $294.2M

Qudian (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QD#NYSE">QD</a>) reported quarterly earnings of $0.10 per share. This is a 190.91 percent increase over losses of $(0.11) per share from the same period last year. The company reported $7.80 million in sales this quarter. This is a 92.26 percent increase over sales of $4.06 million the same period last year.

Earnings

Qudian Q3 Adj. EPADS $0.10 Up From $(0.11) YoY, Sales $7.80M Up From $4.06M YoY

JMP Securities analyst Matthew Carletti downgrades Root (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROOT#NASDAQ">ROOT</a>) from Market Outperform to Market Perform.

ROOT

JMP Securities Downgrades Root to Market Perform

Texas Governor&nbsp;Greg Abbott (R-Texas) has directed state agencies to cease investments in China and divest existing ones. This decision, announced in a letter dated Nov. 21, highlights security and financial risks associated with Chinese investments, 
What Happened: Abbott&#8217;s directive argues that this aggression could elevate the financial risks tied to Chinese investments. The governor&#8217;s letter explicitly bans Texas investing entities from making new investments in China.
Moreover, Abbott has instructed these entities to divest from any current Chinese investments at the earliest feasible opportunity. 
&#8220;Texas will defend and safeguard itself and our public treasury from any potential threat, including those posed by the CCP,&#8221; the statement read.
See Also:&nbsp;<a href="https://www.benzinga.com/24/11/42103633/chinese-court-affirms-cryptocurrency-ownership-as-legal-as-bitcoin-breaks-97k?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Chinese Judge Cites &#8216;High-Pressure Crackdown&#8217; On Speculation In Judgment Declaring Crypto Ownership Legal As Bitcoin Moves Past $97K</a>
Why It Matters: The directive from Governor Abbott comes amid escalating U.S.-China tensions. Recently, the U.S. House of Representatives advanced two Republican bills aiming to reinstate the U.S. Justice Department's "China Initiative." This initiative seeks to <a href="https://www.benzinga.com/news/24/09/40831428/house-gop-advances-bills-to-reinstate-justice-departments-china-initiative-despite-white-house-disap">curb espionage activities</a> targeting U.S. intellectual property and academic institutions. The bills were part of the House Republican's &#8220;China Week,&#8221; which saw over two dozen China-related legislative measures passed.
President-elect Donald Trump has proposed to impose 60% tariff on Chinese goods. Chinese President Xi Jinping recently <a href="https://www.benzinga.com/24/11/42025284/xi-jinping-tells-joe-biden-china-is-ready-to-work-with-trump-as-tariff-threat-looms">expressed a willingness</a> to collaborate with the U.S. government, regardless of the administration in power. This statement was made during a meeting with President Joe Biden at the Asia-Pacific Economic Cooperation forum in Lima. 
Meanwhile, ETFs that allow investment into China have dropped during the past one month. As of Nov. 22nd, according to <a href="https://pro.benzinga.com">Benzinga Pro</a>, the KraneShares CSI China Internet ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KWEB#NYSE">KWEB</a>) has dropped by 5.97% while iShares China Large-Cap ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FXI#NYSE">FXI</a>) fell by 5.13%. Invesco Golden Dragon China ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PGJ#NASDAQ">PGJ</a>) fell by 5.41% and iShares MSCI China ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCHI#NASDAQ">MCHI</a>) dropped by 5.54%.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/tech/24/11/42111283/elon-musks-starlink-faces-new-competition-as-chinese-satellite-firm-spacesail-enters-brazilian-market?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Elon Musk&#8217;s Starlink Faces New Competition As Chinese Satellite Firm Spacesail Enters Brazilian Market</a></li>
</ul>
Disclaimer: This content was partially produced with the help of&nbsp;<a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a>&nbsp;and was reviewed and published by Benzinga editors.
Image via Wikimedia Commons

Government

Global

KWEB

MCHI

PowerShares Golden Dragon Halter USX China Portfolio

Texas Governor Mandates State Agencies To Divest From China: 'Will Defend And Safeguard Itself...From Any Potential Threat'

Needham analyst Quinn Bolton maintains Monolithic Power Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MPWR#NASDAQ">MPWR</a>) with a Buy and lowers the price target from $950 to $600.

MPWR

Needham Maintains Buy on Monolithic Power Systems, Lowers Price Target to $600

Macro Economic Events

Econ #s

Economics

U.K. Services Purchasing Managers Index Preliminary For November 50.0 Vs. 52.3 Est.; 52.0 Prior

U.K. Manufacturing Purchasing Managers Index Preliminary For November 48.6 Vs. 50.1 Est.; 49.9 Prior

U.K. Composite Purchasing Managers' Index Preliminary For November 49.9 Vs. 51.8 Prior

Eurozone Services Purchasing Managers Index Preliminary For November 49.2 Vs. 51.6 Est.; 51.6 Prior

HCOB Eurozone Composite Purchasing Managers Index Preliminary For November 48.1 Vs. 50.0 Prior

Eurozone Manufacturing Purchasing Managers Index Preliminary For November 45.2 Vs. 46.0 Est.; 46.0 Prior

HC Wainwright &amp; Co. analyst Yi Chen reiterates Alpha Tau Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DRTS#NASDAQ">DRTS</a>) with a Buy and maintains $9 price target.

DRTS

HC Wainwright & Co. Reiterates Buy on Alpha Tau Medical, Maintains $9 Price Target

Alzamend Neuro (ALZN) has provided an update. On July 12, 2024, the Company announced a Reverse Stock Split, highlighting that this move is not an ...

Alzamend Neuro Announces Reverse Stock Split Decision

Alzamend Neuro (ALZN) just unveiled an update. Alzamend Neuro, Inc. successfully regained compliance with Nasdaq's Minimum Bid Price Requirement af...

Alzamend Neuro Meets Nasdaq Standards, Embraces Social Media

Warning: ALZN is at high risk of performing badly

Alzamend Neuro regains compliance with Nasdaq

Alzamend Neuro ( ($ALZN) ) has issued an announcement. Alzamend Neuro, a biopharmaceutical company targeting Alzheimer's and other disorders, succe...

Alzamend Neuro Regains Nasdaq Compliance After Strategic Appeal

ALZN

Press Releases

Alzamend Neuro Partners with Massachusetts General Hospital for a Phase II Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, involving Patients with Bipolar Disorder

Alzamend Neuro Partners with Massachusetts General Hospital for Phase II Trial of AL001 involving Patients with Bipolar Disorder and Alzheimer's Disease

Alzamend Neuro Partners with Massachusetts General Hospital for a Phase II Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, involving Patients with Major Depressive Disorder

Alzamend Neuro Partners with Massachusetts General Hospital for Phase II Trial of Next-Generation Treatment for Major Depressive Disorder

Alzamend Neuro Partners with Massachusetts General Hospital for a Phase II Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, involving Patients with Post-Traumatic Stress Disorder

Alzamend Neuro Issues Letter to Stockholders

Alzamend Neuro CEO Stephan Jackman to Participate in the Maxim Group's Virtual Healthcare Conference

Alzamend Neuro Regains Compliance with Nasdaq Listing Standards

Alzamend Neuro Announces Full Data Set from Phase IIA Multiple Ascending Dose Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer's

Alzamend Neuro Announces Full Data Set from its Nonclinical Study: Comparing Brain and Plasma Lithium Exposures between AL001 and Lithium Carbonate in Alzheimer's Transgenic Mice

Comments

Alzamend Neuro

Alzamend Neuro (ALZN) Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO